Lab
Ingenious Personalized Medicine, LLC
Ingenious Personalized Medicine, LLC was paid $1.21M by Medicaid between Jul 2019 and Oct 2024, across 7 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 94% of everything it billed.
33Billing provider infoINGENIOUS PERSONALIZED MEDICINE, LLC
NORTH MIAMI, FL 33161
NORTH MIAMI, FL 33161
33aNPI1598161846assigned 11/14/2014
33bProvider typeClinical Medical Laboratory
28Total paid$1.21M
24GClaims34,042
24DCodes billed7
24AFirst – last monthJul 2019 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#35 of 225
Median peer was paid$74K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SEGAL, SCOTT controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 80 | $173.36 | |
| 2020 | 1,175 | $47K | |
| 2021 | 17,770 | $698K | |
| 2022 | 13,295 | $417K | |
| 2023 | 878 | $29K | |
| 2024incomplete | 844 | $15K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 94% | 19,880 | 14,662 | $1.13M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.0% | 7,977 | 5,985 | $48K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 1,030 | 854 | $14K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 333 | 311 | $9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,418 | 3,147 | $4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 350 | 323 | $360.94 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 54 | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSEGAL, SCOTT (CEO/ PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Compass Colorado Healthcare Systems, INC. | North Miami, FL | $11.62M |
| Compass Health Systems, P.A. | North Miami, FL | $11.16M |
| Compass Carolina Health Systems PA | Charleston, SC | $1.77M |
| Pasadena Eye Associates | Pasadena, TX | $419K |
| Compass Health Systems of Tennessee | Nunnelly, TN | $50K |
| Compass Health Systems, P.A. | North Miami, FL | $30K |
| Compass Colorado Healthcare Systems, INC. | Highlands Ranch, CO | $6K |
| Compass Health Systems, P.A. | Boynton Beach, FL | $6K |
| Compass Health Systems, P.A. | Miami, FL | $6K |
| Compass Colorado Healthcare Systems, INC. | Colorado Springs, CO | $4K |
| Compass Health Systems, P.A. | Pembroke Pines, FL | $3K |
| Compass Health Systems, P.A. | Pembroke Pines, FL | $1K |
| Compass Health Systems, P.A. | Orlando, FL | $1K |
| Compass Colorado Healthcare Systems, INC. | Lone Tree, CO | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.